**Question:** Worst prognosis among all the breast cancer is

A. Triple-negative breast cancer (TNBC)
B. HER2-positive breast cancer
C. Luminal B breast cancer
D. Luminal A breast cancer

**Core Concept:** Breast cancer prognosis is influenced by the molecular subtype of the tumor, which is determined by the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) proteins.

**Why the Correct Answer is Right:** Triple-negative breast cancer (TNBC) is characterized by the absence of ER, PR, and HER2 expression. This results in a poorer prognosis as these tumors lack targets for endocrine therapy (e.g., tamoxifen) and HER2-targeted therapy (e.g., trastuzumab). Additionally, TNBC is more likely to recur early and has a higher rate of distant metastases, leading to a worse overall survival compared to other subtypes.

**Why Each Wrong Option is Incorrect:**

**Option A (HER2-positive breast cancer)**: Although HER2-positive tumors generally have a poorer prognosis compared to hormone receptor-positive tumors, they still have targeted therapy options with trastuzumab and ado-trastuzumab emtansine (T-DM1), which can improve survival outcomes.

**Option B (Luminal B breast cancer)**: Luminal B tumors are characterized by the presence of ER and/or PR and HER2 overexpression or amplification. Although these tumors have a relatively higher grade and Ki-67 index, they still have targeted therapy options with endocrine therapy and trastuzumab.

**Option D (Luminal A breast cancer)**: Luminal A tumors are characterized by the presence of ER and/or PR and HER2 overexpression/amplification but without HER2 overexpression/amplification. These tumors generally have a good prognosis due to the availability of targeted therapy with endocrine therapy.

**Core Concept:** Breast cancer prognosis is influenced by molecular subtype, which is determined by the expression of ER, PR, and HER2 proteins.

**Core Concept:** The overall survival rate and treatment options significantly impact breast cancer prognosis.

**Clinical Pearls:**

Understanding the molecular subtype of breast cancer is crucial for selecting the most appropriate treatment options and improving patient outcomes. Collaborative efforts between surgeons, radiation oncologists, and medical oncologists are vital for developing a tailored treatment plan for each patient based on their molecular subtype.